Oncologist
Dr. Nirmal Raut
Dr. Nirmal Raut is a Medical Oncologist in Mumbai with 20+ years of experience in this field.
Dr. Nirmal Raut
He is currently associated with two hospitals namely Terna Speciality Hospital & Research Centre, Navi Mumbai, and Bhaktivedanta Hospital & Research Centre, Mira Road. He has a special skill in managing various solid and hematological malignancies in adult and pediatric patients. Dr. Nirmal Raut is a distinguished oncologist in Mumbai with a specialization in Radiation Oncology. He completed his MBBS from KEM Hospital and MD in Radiotherapy from Tata Memorial Hospital, Mumbai.
Dr. Nirmal Raut has served in leading institutions such as Tata Memorial Hospital, Asian Institute of Medical Sciences, Bhaktivedanta Hospital & Research Centre, and Jupiter Hospital. His expertise extends to clinical research, with publications on brainstem glioma, lung cancer epidemiology, and breast cancer treatment. A certified member of the European Society of Medical Oncology (ESMO), he also holds a Master’s in Molecular Oncology from Spain, showcasing his dedication to advancing cancer treatment through knowledge and innovation.
- Radiation Oncology
- Precision Oncology
- Immunotherapy
- Lung Cancer
- Breast Cancer/Gynaec. Cancer
- Head and Neck cancer
- Colorectal and Hepatobiliary cancer
- Genitourinary cancer
- Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).
- Comprehensive ctDNA analysis to identify genome-instability and actionable mutation landscape in gynecologic cancers.
- Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.
- Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.
- Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.
- Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden.
- Identification of novel actionable SNVs via targeted comprehensive genome profiling in patients with gallbladder and cholangiocarcinoma cancer.